Technical Data
N2108-77B-P
Neuregulin 3 (NRG3, HGNC:7999, HRG3, pro-NRG3) (Control Peptide)
100ug
|
Technical Data |
|
N2108-77B-P |
Neuregulin 3 (NRG3, HGNC:7999, HRG3, pro-NRG3) (Control Peptide) |
100ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: Blue Ice |
|
C-terminus, aa RNEIQRDSALTK. Control peptide corresponding to polyclonal antibody, Catalog#N2108-77B, goat x human. Applications: Suitable for use in ELISA. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. Peptide Blocking (see corresponding antibody N2108-77B): Antibodies are typically supplied at 0.5mg/ml and peptides as a 100ul pellet. When peptides are reconstituted in 200ul water, the concentration would be also 0.5mg/ml. To start, the best ratio would be 1:1 (which means molar excess of peptides relative to antibodies when identical volumes are mixed). Mix equal volumes of peptide and antibody at the required dilution and leave at ambient temperature. It is best is to have two identical blots, to be incubated with equal amount of antibodies, but one with the antibodies pre-adsorbed to the peptide for 20min. Then incubate and develop the two blots in parallel. |
Purity: Highly Purified Concentration: ~0.5mg/ml Form: Supplied as a lyophilized powder in PBS. Specificity: Recognizes human Neuregulin 3. Species Crossreactivity: mouse, rat, canine. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
NRG-3 in human breast cancers: activation of multiple erbB family proteins., Hijazi MM, Young PE, Dougherty MK, Bressette DS, Cao TT, Pierce JH, Wong LM, Alimandi M, King CR. , Int J Oncol. 1998 Nov;13(5):1061-7.
|
||